Published 2023-01-01
“…Jun Lu,1– 4,* Yuqing Lou,1,* Yanwei Zhang,1,* Runbo Zhong,1 Wei Zhang,1 Xueyan Zhang,1 Huimin Wang,1 Tianqing Chu,1 Baohui Han,1– 3
Hua Zhong1,3 1Department of Pulmonary Medicine, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao
Tong University, Shanghai, People’s Republic of China; 2Shanghai Institute of Thoracic Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao
Tong University, Shanghai, People’s Republic of China; 3Translational Medical Research Platform for Thoracic Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao
Tong University, Shanghai, People’s Republic of China; 4Department of Bio-Bank, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao
Tong University, Shanghai, People’s Republic of China*These
authors contributed equally to this workCorrespondence: Baohui Han;
Hua Zhong, Department of Pulmonary Medicine, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao
Tong University, Shanghai, 200030, People’s Republic of China, Email xkyyhan@gmail.com; 18930858216@163.com; eddiedong8@hotmail.comBackground: Nanocarrier platforms have been indicated to have great potential in clinical practice to treat non-small cell lung cancer (NSCLC). …”
Get full text
Article